Cargando…
Safety and pharmacodynamic efficacy of eculizumab in aneurysmal subarachnoid hemorrhage (CLASH): A phase 2a randomized clinical trial
INTRODUCTION: Complement C5 antibodies reduce brain injury after experimental subarachnoid hemorrhage. PATIENTS AND METHODS: In this randomized, controlled, open-label, phase 2a clinical trial with blinded-outcome assessment, we included adult aneurysmal subarachnoid hemorrhage (aSAH) patients admit...
Autores principales: | Koopman, Inez, Tack, Reinier WP, Wunderink, Herman F, Bruns, Anke HW, van der Schaaf, Irene C, Cianci, Daniela, Gelderman, Kyra A, van de Ridder, Inge M, Hol, Elly M, Rinkel, Gabriel JE, Vergouwen, Mervyn DI |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683736/ https://www.ncbi.nlm.nih.gov/pubmed/37606053 http://dx.doi.org/10.1177/23969873231194123 |
Ejemplares similares
-
CompLement C5 Antibodies for decreasing brain injury after aneurysmal Subarachnoid Haemorrhage (CLASH): study protocol for a randomised controlled phase II clinical trial
por: Koopman, Inez, et al.
Publicado: (2020) -
Aneurysm characteristics and risk of rebleeding after subarachnoid
haemorrhage
por: Koopman, Inez, et al.
Publicado: (2018) -
Devastating delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage
por: Koopman, Inez, et al.
Publicado: (2022) -
Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
por: Wijnsma, Kioa Lente, et al.
Publicado: (2019) -
Glial cell response and microthrombosis in aneurysmal subarachnoid hemorrhage patients: An autopsy study
por: Koopman, Inez, et al.
Publicado: (2023)